Drug cocktail may cut transfusions for kids with thalassemia
NCT ID NCT06299670
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether giving children with transfusion-dependent thalassemia a combination of hydroxyurea and thalidomide works better than either drug alone. Ninety children aged 3-18 were split into three groups: one getting both drugs, one getting only hydroxyurea, and one getting only thalidomide. Researchers measured changes in hemoglobin levels, transfusion frequency, and iron levels after three months to see which approach was most effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hydroxyurea and Thalidomide
What this could lead to
If successful, this combination could reduce the need for blood transfusions in children with thalassemia, improving their quality of life.
What could go wrong
This is a small, single-center trial with only 90 participants. Results may not apply to all patients, and side effects from the drugs are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSFUSION-DEPENDENT THALASSEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bangabandhu Sheikh Mujib Medical University
Dhaka, 1000, Bangladesh